All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion ...

If and how nutrient preference impacts cell identity has been a longstanding mystery for scientists—until a team of Salk ...

29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate Therapeutics” or the "Company”), a clinical-stage ...

This research investigates the molecular mechanisms by which SMAD2/3-SMYD2 and developmental transcription factors cooperate ...

(NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular ...

29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced ...